A novel HLA-A2-restricted CTL epitope of tumor-associated antigen L6 can inhibit tumor growth in vivo

Journal of Immunotherapy

Volumn 35, Issue 3, 2012, Pages 235-244

  Tu, Shih Hsin ^a,b   Huang, Hsing I ^c   Lin, Su I ^d   Liu, Hsin Yu ^d   Sher, Yuh Pyng ^e   Chiang, Sheng Kuo ^d   Chong, Pele ^d   Roffler, Steve ^f   Tseng, Guan Chin ^g   Chen, Hsin Wei ^d,g   Liu, Shih Jen ^d,g  

^a CATHAY GENERAL HOSPITAL   (Taiwan)

^b TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^c CHANG GUNG UNIVERSITY   (Taiwan)

^d NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^e CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^f INSTITUTE OF BIOMEDICAL SCIENCES   (Taiwan)

^g CHINA MEDICAL UNIVERSITY   (Taiwan)

Author keywords

cytotoxic T lymphocytes; peptide; TAL6

Indexed keywords

ALANYLLYSYLPHENYLALANYLVALYLALANYLALANYLTRYPTOPHYLTHREONYLLEUCYLLYSYLALANYLALANYLALANINE; CANCER VACCINE; DNA VACCINE; EPITOPE; GAMMA INTERFERON; HLA A2 ANTIGEN; LEUCYLLEUCYLMETHIONYLLEUCYLLEUCYLPROLYLALANYLPHENYLALANYLVALINE; LYSOSOME ASSOCIATED MEMBRANE PROTEIN 1; PEPTIDE VACCINE; PLASMID DNA; SERYLLEUCYLVALYLGLYCYLLEUCYLALANYLLEUCYLLEUCYLCYSTEINE; SYNTHETIC PEPTIDE; TUMOR ANTIGEN; TUMOR ASSOCIATED ANTIGEN L6; UNCLASSIFIED DRUG;

ADULT; AGED; ALGORITHM; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; ANTIGEN PRESENTATION; ARTICLE; BREAST CANCER; CANCER IMMUNIZATION; CANCER INHIBITION; CANCER TISSUE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOLYSIS; CYTOTOXIC T LYMPHOCYTE; DNA IMMUNIZATION; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME LINKED IMMUNOSPOT ASSAY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOSTIMULATION; IN VIVO STUDY; MAJOR HISTOCOMPATIBILITY COMPLEX RESTRICTION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN MOTIF; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SPLEEN CELL; T LYMPHOCYTE; WILD TYPE;

AMINO ACID SEQUENCE; ANIMALS; ANTIGENS, SURFACE; BREAST NEOPLASMS; CANCER VACCINES; CELL LINE, TUMOR; CYTOTOXICITY, IMMUNOLOGIC; EPITOPES, T-LYMPHOCYTE; FEMALE; GENE EXPRESSION; HLA-A2 ANTIGEN; HUMANS; MICE; MICE, TRANSGENIC; NEOPLASM PROTEINS; PEPTIDES; PROTEIN BINDING; T-LYMPHOCYTES, CYTOTOXIC; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84863377785     PISSN: 15249557     EISSN: 15374513     Source Type: Journal    
DOI: 10.1097/CJI.0b013e318248f2ae     Document Type: Article

References (47)

1. Hellstrom I, Beaumier PL, Hellstrom KE. Antitumor effects of L6, an IgG2a antibody that reacts with most human carcinomas. Proc Natl Acad Sci USA. 1986;83:7059-7063. (Pubitemid 16002369)
2. DeNardo SJ, DeNardo GL, Miers LA, et al. Development of tumor targeting bioprobes ((111)In-chimeric L6 monoclonal antibody nanoparticles) for alternating magnetic field cancer therapy. Clin Cancer Res. 2005;11:7087s-7092s. (Pubitemid 41428709)
3. DeNardo SJ, DeNardo GL, Natarajan A, et al. Thermal dosimetry predictive of efficacy of 111In-ChL6 nanoparticle AMF-induced thermoablative therapy for human breast cancer in mice. J Nucl Med. 2007;48:437-444. (Pubitemid 47604930)
4. Denardo SJ, O'Grady LF, Richman CM, et al. Radioimmunotherapy for advanced breast cancer using I-131-ChL6 antibody. Anticancer Res. 1997;17:1745-1751. (Pubitemid 27263155)
5. DeNardo SJ, Warhoe KA, O'Grady LF, et al. Radioimmunotherapy for breast cancer: treatment of a patient with I-131 L6 chimeric monoclonal antibody. Int J Biol Markers. 1991;6:221-230.
6. Goodman GE, Hellstrom I, Brodzinsky L, et al. Phase I trial of murine monoclonal antibody L6 in breast, colon, ovarian, and lung cancer. J Clin Oncol. 1990;8:1083-1092. (Pubitemid 20200197)
7. Goodman GE, Hellstrom I, Yelton DE, et al. Phase I trial of chimeric (human-mouse) monoclonal antibody L6 in patients with non-small-cell lung, colon, and breast cancer. Cancer Immunol Immunother. 1993;36:267-273. (Pubitemid 23069247)
8. Ziegler LD, Palazzolo P, Cunningham J, et al. Phase I trial of murine monoclonal antibody L6 in combination with subcutaneous interleukin-2 in patients with advanced carcinoma of the breast, colorectum, and lung. J Clin Oncol. 1992;10:1470-1478. (Pubitemid 23059931)
9. Lekishvili T, Fromm E, Mujoomdar M, et al. The tumourassociated antigen L6 (L6-Ag) is recruited to the tetraspaninenriched microdomains: implication for tumour cell motility. J Cell Sci. 2008;121:685-694. (Pubitemid 351524167)
10. Chang YW, Chen SC, Cheng EC, et al. CD13 (aminopeptidase N) can associate with tumor-associated antigen L6 and enhance the motility of human lung cancer cells. Int J Cancer. 2005;116:243-252.
11. Kao Y-R, Shih J-Y, WenW-C, et al. Tumor-associated antigen L6 and the invasion of human lung cancer cells. Clin Cancer Res. 2003;9:2807-2816. (Pubitemid 36842127)
12. Shih SC, Zukauskas A, Li D, et al. The L6 protein TM4SF1 is critical for endothelial cell function and tumor angiogenesis. Cancer Res. 2009;69:3272-3277.
13. Bae S, Shim SH, Park CW, et al. Combined omics analysis identifies transmembrane 4 L6 family member 1 as a surface protein marker specific to human mesenchymal stem cells. Stem Cells Dev. 2011;20:197-203.
14. Simpson NE, Lambert WM, Watkins R, et al. High levels of Hsp90 cochaperone p23 promote tumor progression and poor prognosis in breast cancer by increasing lymph node metastases and drug resistance. Cancer Res. 2010;70:8446-8456.
15. Brossart P, Wirths S, Brugger W, et al. Dendritic cells in cancer vaccines. Exp Hematol. 2001;29:1247-1255. (Pubitemid 33033301)
16. Efferson CL, Schickli J, Ko BK, et al. Activation of tumor antigen-specific cytotoxic T lymphocytes (CTLs) by human dendritic cells infected with an attenuated influenza A virus expressing a CTL epitope derived from the HER-2/neu protooncogene. J Virol. 2003;77:7411-7424. (Pubitemid 36734510)
17. Kass R, Agha J, Bellone S, et al. In vitro induction of tumorspecific HLA class I-restricted CD8+ cytotoxic T lymphocytes from patients with locally advanced breast cancer by tumor antigen-pulsed autologous dendritic cells. J Surg Res. 2003; 112:189-197. (Pubitemid 36904045)
18. Amarnath SM, Dyer CE, Ramesh A, et al. In vitro quantification of the cytotoxic T lymphocyte response against human telomerase reverse transcriptase in breast cancer. Int J Oncol. 2004;25:211-217.
19. Bharat A, Benshoff N, Fleming TP, et al. Characterization of the role of CD8+ T cells in breast cancer immunity following mammaglobin-A DNA vaccination using HLA-class-I tetramers. Breast Cancer Res Treat. 2008;110:453-463. (Pubitemid 351962588)
20. Jager D, Karbach J, Pauligk C, et al. Humoral and cellular immune responses against the breast cancer antigen NY-BR-1: definition of two HLA-A2 restricted peptide epitopes. Cancer Immun. 2005;5:11.
21. Jaramillo A, Narayanan K, Campbell LG, et al. Recognition of HLA-A2-restricted mammaglobin-A-derived epitopes by CD8+ cytotoxic T lymphocytes from breast cancer patients. Breast Cancer Res Treat. 2004;88:29-41. (Pubitemid 39524442)
22. Blake-Mortimer JS, Sephton SE, Carlson RW, et al. Cytotoxic T lymphocyte count and survival time in women with metastatic breast cancer. Breast J. 2004;10:195-199. (Pubitemid 38715734)
23. Svane I, Pedersen A, Johansen J, et al. Vaccination with p53 peptide-pulsed dendritic cells is associated with disease stabilization in patients with p53 expressing advanced breast cancer; monitoring of serum YKL-40 and IL-6 as response biomarkers. Cancer Immunol Immunother. 2007;56: 1485-1499. (Pubitemid 47024713)
24. Rammensee HG, Bachmann J, Emmerich NPN, et al. SYFPEITHI: database for MHC ligands and peptide motifs. Immunogenetics. 1999;50:213-219. (Pubitemid 30099526)
25. Buus S, Lauemoller SL, Worning P, et al. Sensitive quantitative predictions of peptide-MHC binding by a "Query by Committee" artificial neural network approach. Tissue Antigens. 2003;62:378-384. (Pubitemid 37345160)
26. Christensen JK, Lamberth K, Nielsen M, et al. Selecting informative data for developing peptide-MHC binding predictors using a query by committee approach. Neural Comput. 2003;15:2931-2942. (Pubitemid 37379001)
27. Lundegaard C, Nielsen M, Lund O. The validity of predicted T-cell epitopes. Trends Biotechnol. 2006;24:537-538. (Pubitemid 44781247)
28. Reche PA, Glutting J-P, Reinherz EL. Prediction of MHC class I binding peptides using profile motifs. Human Immunol. 2002;63:701-709. (Pubitemid 34983301)
29. Reche PA, Glutting J-P, Zhang H, et al. Enhancement to the RANKPEP resource for the prediction of peptide binding to MHC molecules using profiles. Immunogenetics. 2004;56: 405-419. (Pubitemid 39359226)
30. Ressing M, Sette A, Brandt R, et al. Human CTL epitopes encoded by human papillomavirus type 16 E6 and E7 identified through in vivo and in vitro immunogenicity studies of HLA-A*0201-binding peptides. J Immunol. 1995; 154:5934-5943.
31. Chen HW, Leng CH, Liu HY, et al. Identification of HLAA11-restricted CTL epitopes derived from HPV type 18 using DNA immunization. Cancer Biol Ther. 2009;8:2025-2032.
32. Lee C-H, Huang C-S, Chen C-S, et al. Overexpression and activation of the a9-nicotinic receptor during tumorigenesis in human breast epithelial cells. J Natl Cancer Inst. 2010; 102:1322-1335.
33. Betts MR, Price DA, Brenchley JM, et al. The functional profile of primary human antiviral CD8+ T cell effector activity is dictated by cognate peptide concentration. J Immunol. 2004;172:6407-6417. (Pubitemid 38621250)
34. Ruitenberg JJ, Ghanekar SA, Brockstedt DG, et al. Simultaneous detection of murine antigen-specific intracellular cytokines and CD107a/CD107b by flow cytometry. Nature Prot. 2007.
35. Mittendorf EA, Storrer CE, Shriver CD, et al. Evaluation of the CD107 cytotoxicity assay for the detection of cytolytic CD8+ cells recognizing HER2/neu vaccine peptides. Breast Cancer Res Treat. 2005;92:85-93. (Pubitemid 40875083)
36. Hellstrom I, Horn D, Linsley P, et al. Monoclonal mouse antibodies raised against human lung carcinoma. Cancer Res. 1986;46:3917-3923. (Pubitemid 16075885)
37. Howell LP, DeNardo SJ, Levy NB, et al. Immunohistochemical staining of metastatic ductal carcinomas of the breast by monoclonal antibodies used in imaging and therapy: A comparative study. Int J Biol Markers. 1995; 10:129-135.
38. Parker K, Bednarek M, Coligan J. Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide side-chains. J Immunol. 1994;152: 163-175.
39. DeNardo SJ, Gumerlock PH, Winthrop MD, et al. Yttrium-90 chimeric L6 therapy of human breast cancer in nude mice and apoptosis-related messenger RNA expression. Cancer Res. 1995;55:5837s-5841s.
40. DeNardo SJ, Kukis DL, Miers LA, et al. Yttrium-90-DOTApeptide-chimeric L6 radioimmunoconjugate: efficacy and toxicity in mice bearing p53 mutant human breast cancer xenografts. J Nucl Med. 1998;39:842-849. (Pubitemid 28216735)
41. Ferris RL, Jaffee EM, Ferrone S. Tumor antigen-targeted, monoclonal antibody-based immunotherapy: clinical response, cellular immunity, and immunoescape. J Clin Oncol:Off J Am Soc Clin Oncol. 2010;28:4390-4399.
42. Correale P, Walmsley K, Nieroda C, et al. In vitro generation of human cytotoxic T lymphocytes specific for peptides derived from prostate-specific antigen. J Natl Cancer Inst. 1997; 89:293-300. (Pubitemid 27085891)
43. Theobald M, Biggs J, Dittmer D, et al. Targeting p53 as a general tumor antigen. Proc Natl Acad Sci USA. 1995;92: 11993-11997. (Pubitemid 26013997)
44. Wedemeyer H, Gagneten S, Davis A, et al. Oral immunization with HCV-NS3-transformed Salmonella: induction of HCVspecific CTL in a transgenic mouse model. Gastroenterology. 2001;121:1158-1166. (Pubitemid 33022096)
45. Alexander J, Del Guercio MF, Fikes JD, et al. Recognition of a novel naturally processed, A2 restricted, HCV-NS4 epitope triggers IFN-gamma release in absence of detectable cytopathicity. Hum Immunol. 1998;59:776-782. (Pubitemid 28512545)
46. Guidotti LG, Ando K, Hobbs MV, et al. Cytotoxic T lymphocytes inhibit hepatitis B virus gene expression by a noncytolytic mechanism in transgenic mice. Proc Natl Acad Sci USA. 1994;91:3764-3768. (Pubitemid 24139512)
47. Jo J, Aichele U, Kersting N, et al. Analysis of CD8+ T-cellmediated inhibition of hepatitis C virus replication using a novel immunological model. Gastroenterology. 2009;136:1391-1401.